Skip to main content

Blood therapy giant CSL reports better than expected NPAT | CSL (ASX:CSL) Reporting Results

Jessica Amir
August 18, 2021

The biggest blood therapy company in the world and the second biggest vaccine company, CSL (ASX:CSL) reported its FY21 results.

CSL reported its NPAT jumped 13% to US$2.375 billion. This is 2% above market expectations. Profit growth was boosted by CSL’s Seqirus division, its flu vaccine business, which saw a 30% revenue boost. However, CSL’s Behring division, its blood therapy business, was severely impacted by COVID-19 restrictions.

CSL’s group revenue rose 13% to US$10.3 billion, while CSL’s cashflow from operations surged 46% to US$3.6 billion.

CSL declared a final dividend of US$1.18ps (AU$1.61ps), payable on 30th September. CSL’s total full year dividends increased 10% to US$2.22 per share.

CSL’s FY22 outlook views profit to fall between US$2.15 billion to US$2.25 billion.

CSL is a Morgan Stanley, Macquarie, Citi and Credit Suisse HOLD stock. UBS and Morgans have CSL as a BUY stock.

CSL shares surged to $302.80, at its highest level since June. However, traders quickly took profits, and CSL is now trading at $294.83.

Morning Bell 7 February

Grady Wulff
February 7, 2024

Morning Bell 6 February

Grady Wulff
February 6, 2024

Morning Bell 5 February

Sam Kanaan
February 5, 2024

Weekly Wrap 2 February

Grady Wulff
February 2, 2024

Morning Bell 2 February

Sam Kanaan
February 2, 2024

Morning Bell 1 February

Sam Kanaan
February 1, 2024

Morning Bell 31 January

Grady Wulff
January 31, 2024

Morning Bell 30 January

Grady Wulff
January 30, 2024

Morning Bell 29 January

Grady Wulff
January 29, 2024

Morning Bell 25 January

Sam Kanaan
January 25, 2024

Morning Bell 24 January

Grady Wulff
January 24, 2024

Morning Bell 23 January

Grady Wulff
January 23, 2024